Edgewise Therapeutics, Inc., a biopharmaceutical company, develops small molecule therapies for musculoskeletal diseases. The Company''s lead product candidate, EDG-5506, is an orally administered small molecule designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy and Becker muscular dystrophy which has completed Phase 1 clinical trial. It develops a pipeline of precision medicine product candidates that target key muscle proteins and modulators to address genetically defined muscle disorders. Edgewise Therapeutics, Inc. was incorporated in 2017 and is headquartered in Boulder, Colorado.
Latest shares articles
GBP/USD attempts recovery as UK CPI rises once again
UK inflation rose unexpectedly in June, moving further away from the Bank of England's 2% and limiting the amount of future rate cuts
08:25, 16 July 2025
EUR/USD: bullish narrative tested by U.S. trade threats
US tariff threats weigh on euro sentiment as the dollar regains the upper hand
07:47, 15 July 2025
US CPI Preview: Inflation data to test Fed’s tariff assumptions and policy expectations
US CPI data could impact the Fed's views on tariffs, inflation and monetary policy
18:52, 14 July 2025
Cocoa price prediction: Third-party target
Read our cocoa price forecast for 2025 and beyond, with insights from third-party analysts and commodities market experts.
15:59, 14 July 2025
Ratings and Reviews
Ratings and Reviews
